The INVESTED Trial is designed to determine which of two formulations of influenza vaccine, the standard dose or an investigational higher dose, is more effective in reducing deaths and heart- or lung-related admissions to the hospital.
Influenza and Heart Disease

Influenza "flu" can lead to complications like hospitalizations and/or death, particularly in individuals with heart disease. In fact, influenza-related death is more common in people with heart disease than any other chronic health condition. 

Trial News
1/31/19 INVESTED 2018-19 enrollment season ended with a total of 5386 participants enrolled!
9/24/18 First new participant enrolled for the 2018-19 season!
5/22/18 INVESTED Trial Design Paper published in American Heart Journal